Vinorelbine tartrate is under clinical development by Taiwan Liposome and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vinorelbine tartrate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vinorelbine tartrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vinorelbine tartrate overview

Vinorelbine tartrate (TLC-178) is under development for the treatment of solid tumors, lymphomas including peripheral T cell lymphoma, cutaneous T-cell lymphoma, soft tissue sarcoma including childhood rhabdomyosarcoma and solid tumor like non-small cell lung carcinoma. It is administered intravenously. The drug candidate is a liposomal encapsulated formulation of vinorelbine. Vinorelbine is a vinca alkaloid. The drug candidate is based on NanoX technology.

Taiwan Liposome overview

Taiwan Liposome (TLC) is a clinical-stage pharmaceutical company, which develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and infectous disease. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan.

Quick View Vinorelbine tartrate LOA Data

Report Segments
  • Innovator
Drug Name
  • Vinorelbine tartrate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.